Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 24258060)

1.

Enhancement of DC-mediated anti-leukemic immunity in vitro by WT1 antigen and CpG co-encapsulated in PLGA microparticles.

Zhang L, Zhao S, Duan J, Hu Y, Gu N, Xu H, Yang XD.

Protein Cell. 2013 Dec;4(12):887-9. doi: 10.1007/s13238-013-3916-x. No abstract available.

PMID:
24258060
2.

Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles.

Kokate RA, Thamake SI, Chaudhary P, Mott B, Raut S, Vishwanatha JK, Jones HP.

Nanomedicine (Lond). 2015;10(6):915-29. doi: 10.2217/nnm.14.144.

PMID:
25867857
3.

Defining MHC class II T helper epitopes for WT1 tumor antigen.

Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, Celis E.

Cancer Immunol Immunother. 2006 Jul;55(7):850-60. Epub 2005 Oct 12.

PMID:
16220325
4.

Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.

Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold B, Keskin DB, Reinherz EL, Sasada T.

Biomaterials. 2011 May;32(14):3666-78. doi: 10.1016/j.biomaterials.2011.01.067. Epub 2011 Feb 23.

PMID:
21345488
5.

"Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.

Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J.

J Immunother. 2007 May-Jun;30(4):378-95.

PMID:
17457213
6.

Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.

San Román B, Irache JM, Gómez S, Tsapis N, Gamazo C, Espuelas MS.

Eur J Pharm Biopharm. 2008 Sep;70(1):98-108. doi: 10.1016/j.ejpb.2008.03.015. Epub 2008 Mar 31.

PMID:
18501572
7.

Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Osada T, Woo CY, McKinney M, Yang XY, Lei G, Labreche HG, Hartman ZC, Niedzwiecki D, Chao N, Amalfitano A, Morse MA, Lyerly HK, Clay TM.

Clin Cancer Res. 2009 Apr 15;15(8):2789-96. doi: 10.1158/1078-0432.CCR-08-2589. Epub 2009 Apr 7.

8.

Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.

Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J.

J Drug Target. 2003;11(8-10):495-507.

PMID:
15203918
9.

Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.

Ma W, Smith T, Bogin V, Zhang Y, Ozkan C, Ozkan M, Hayden M, Schroter S, Carrier E, Messmer D, Kumar V, Minev B.

J Transl Med. 2011 Mar 31;9:34. doi: 10.1186/1479-5876-9-34.

10.

Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.

Hamdy S, Haddadi A, Hung RW, Lavasanifar A.

Adv Drug Deliv Rev. 2011 Sep 10;63(10-11):943-55. doi: 10.1016/j.addr.2011.05.021. Epub 2011 Jun 6. Review.

PMID:
21679733
11.

WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission.

Hashii Y, Sato-Miyashita E, Matsumura R, Kusuki S, Yoshida H, Ohta H, Hosen N, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Ozono K.

Leukemia. 2012 Mar;26(3):530-2. doi: 10.1038/leu.2011.226. Epub 2011 Aug 26. No abstract available.

PMID:
21869838
12.

WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.

Oka Y, Tsuboi A, Fujiki F, Li Z, Nakajima H, Hosen N, Shirakata T, Nishida S, Oji Y, Kawase I, Sugiyama H.

Anticancer Agents Med Chem. 2009 Sep;9(7):787-97. Epub 2009 Sep 1. Review.

PMID:
19538172
13.
14.

Spray-dried chitosan microparticles for cellular delivery of an antigenic protein: physico-chemical properties and cellular uptake by dendritic cells and macrophages.

Kusonwiriyawong C, Lipipun V, Vardhanabhuti N, Zhang Q, Ritthidej GC.

Pharm Res. 2013 Jun;30(6):1677-97. doi: 10.1007/s11095-013-1014-7. Epub 2013 Mar 13.

PMID:
23483441
15.

Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles.

Prasad S, Cody V, Saucier-Sawyer JK, Fadel TR, Edelson RL, Birchall MA, Hanlon DJ.

Pharm Res. 2012 Sep;29(9):2565-77. doi: 10.1007/s11095-012-0787-4. Epub 2012 Jul 14.

16.

Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.

Molavi O, Mahmud A, Hamdy S, Hung RW, Lai R, Samuel J, Lavasanifar A.

Mol Pharm. 2010 Apr 5;7(2):364-74. doi: 10.1021/mp900145g.

PMID:
20030320
17.

[Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].

Gu WY, Cao XS, Qiu GQ, Chen ZX, Sheng LX, Xie XB, He J, Cen JN, Shen HL.

Zhonghua Yi Xue Za Zhi. 2005 Dec 28;85(49):3475-80. Chinese.

PMID:
16686063
18.

WT1 as a novel target antigen for cancer immunotherapy.

Oka Y, Tsuboi A, Elisseeva OA, Udaka K, Sugiyama H.

Curr Cancer Drug Targets. 2002 Mar;2(1):45-54. Review.

PMID:
12188920
19.

Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia.

Pospísilová D, Borovicková J, Poloucková A, Spísek R, Sedivá A, Hrusák O, Starý J, Bartůnková J.

Cancer Immunol Immunother. 2002 Apr;51(2):72-8. Epub 2002 Jan 29.

PMID:
11904731
20.

Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.

Macho Fernandez E, Chang J, Fontaine J, Bialecki E, Rodriguez F, Werkmeister E, Krieger V, Ehret C, Heurtault B, Fournel S, Frisch B, Betbeder D, Faveeuw C, Trottein F.

Int J Pharm. 2012 Feb 14;423(1):45-54. doi: 10.1016/j.ijpharm.2011.04.068. Epub 2011 May 14.

PMID:
21575695
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk